Close Menu

NEW YORK – 23andMe has laid off approximately 100 employees, about 14 percent of its workforce, the direct-to-consumer genetic testing company confirmed on Thursday.

According to a spokesperson, the layoffs occurred across the company's consumer business, which is being restructured, but did not affect its therapeutics business.

Going forward, 23andMe will focus its activities on its core businesses, consumer genomics and therapeutics, and plans to scale back on non-core activities, such as clinical trials, the spokesperson said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.